Gilead stock rise not as bullish after Remdesivir trial in China ’Flops’

Gilead stock rise not as bullish after Remdesivir trial in China ’Flops’

A clinical trial in China of Gilead’s Remdesivir is cut short due to disappointing expectations, prompting a sharp response from Gilead explaining the trial was cut short due to the low amount of trial participants. Gilead’s stock takes a minor hit.

Steve
Steve
Top in Business
Get the App